1. National
Cancer Institute. What is cancer? [Internet]. National Cancer Institute.
National Institutes of Health; 2021. Available from: https://www.cancer.gov/about-cancer/understanding/what-is-cancer
2. Hanahan
D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46. doi:
10.1158/2159-8290.CD-21-1059.
3. Mayo
Clinic. Cancer - Symptoms and Causes [Internet]. Mayo Clinic. Mayo Clinic;
2022. Available from: https://www.mayoclinic.org/diseases-conditions/cancer/symptoms-causes/syc-20370588
4. Li
S, Young KH, Medeiros LJ. Diffuse large B-cell lymphoma. Pathology. 2018 Jan;50(1):74–87.
5. Crump,
M. et al. Outcomes in refractory diffuse large B-cell lymphoma: Results from
the international SCHOLAR-1 study. Blood 130, 1800–1808.
https://doi.org/10.1182/blood-2017-03-769620 (2017).
6. Research
C for DE and. FDA approves treatment for relapsed or refractory diffuse large
B-cell lymphoma and high-grade B-cell lymphoma. FDA [Internet]. 2023 Jun 8;
Available from:
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell
7. Genmab
US, Inc. Epkinly (epcoritamab-bysp) injection, for subcutaneous use.
Prescribing Information. Plainsboro, NJ: Genmab US; revised May 2023.
8. Thieblemont
C, Phillips T, Ghesquieres H, Cheah CY, Clausen MR, Cunningham D, Do YR, Feldman
T, Gasiorowski R, Jurczak W, Kim TM, Lewis DJ, van der Poel M, Poon ML, Cota
Stirner M, Kilavuz N, Chiu C, Chen M, Sacchi M, Elliott B, Ahmadi T, Hutchings
M, Lugtenburg PJ: Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific
T-Cell-Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose
Expansion in a Phase I/II Trial. J Clin Oncol. 2023 Apr 20;41(12):2238-2247.
doi: 10.1200/JCO.22.01725. Epub 2022 Dec 22.
9. FDA
Approved Drug Products: EPKINLY (epcoritamab-bysp) injection for subcutaneous
use (May 2023)
10. Chiu
CW, Hiemstra IH, W. ten Hagen, R. Snijdewint‐Nkairi, B. de Jong, P. Garrido
Castro, et al. PRECLINICAL EVALUATION OF EPCORITAMAB COMBINED WITH STANDARD OF
CARE AGENTS FOR THE TREATMENT OF B‐CELL LYMPHOMAS. Hematological Oncology. 2021
Jun 1;39(S2).
11. Hutchings
M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, et al. Dose
escalation of subcutaneous epcoritamab in patients with relapsed or refractory
B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. The Lancet [Internet].
2021 Sep 25 [cited 2021 Dec 8];398(10306):1157–69. Available from: https://www.sciencedirect.com/science/article/pii/S0140673621008898?via%3Dihub
12. Swerdlow
SH, Campo E, Pileri SA, et al: The 2016 revision of the World Health
Organization classification of lymphoid neoplasms. Blood 127:2375-2390, 2016
13. Cheson
BD, Fisher RI, Barrington SF, et al: Recommendations for initial evaluation,
staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The
Lugano classification. J Clin Oncol 32:3059-3067, 2014
14. Coiffier
B, Altman A, Pui CH, et al: Guidelines for the management of pediatric and
adult tumor lysis syndrome: An evidence-based review. J Clin Oncol
26:2767-2778, 2008
15. Lee
DW, Santomasso BD, Locke FL, et al: ASTCT consensus grading for cytokine
release syndrome and neurologic toxicity associated with immune effector cells.
Biol Blood Marrow Transplant 25:625-638, 2019
16. Thieblemont C, Phillips T, Ghesquieres
H, Cheah CY, Clausen MR, Cunningham D, et al. Epcoritamab, a Novel,
Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or
Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial. Journal
of Clinical Oncology. 2022 Dec 22;
17. A Phase 3 Trial of Epcoritamab vs
Investigator’s Choice Chemotherapy in R/R DLBCL - Full Text View -
ClinicalTrials.gov [Internet]. clinicaltrials.gov. [cited 2024 Feb 16].
Available from: https://classic.clinicaltrials.gov/ct2/show/NCT04628494
18. Research C for DE and. FDA approves
treatment for relapsed or refractory diffuse large B-cell lymphoma and
high-grade B-cell lymphoma. FDA [Internet]. 2023 Jun 8; Available from: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell
19. ESMO. FDA Grants Accelerated
Approval to Epcoritamab-bysp for Relapsed or Refractory Diffuse Large B-Cell
Lymphoma and High-Grade B-Cell Lymphoma [Internet]. www.esmo.org. [cited 2024
Feb 17]. Available from: https://www.esmo.org/oncology-news/fda-grants-accelerated-approval-to-epcoritamab-bysp-for-relapsed-or-refractory-diffuse-large-b-cell-lymphoma-and-high-grade-b-cell-lymphoma
20. AM TAPSP 5/22/2023 10:21:00 ALU
5/22/2023 11:17:07. FDA Grants Accelerated Approval to Epcoritamab-bysp for
Relapsed or Refractory B-Cell Lymphoma - The ASCO Post [Internet].
ascopost.com. [cited 2024 Feb 17]. Available from: https://ascopost.com/news/may-2023/fda-grants-accelerated-approval-to-epcoritamab-bysp-for-relapsed-or-refractory-b-cell-lymphoma/
21. DailyMed - EPKINLY- epcoritamab-bysp
injection, solution EPKINLY- epcoritamab-bysp injection, solution, concentrate
[Internet]. dailymed.nlm.nih.gov. Available from: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a
22. These highlights do not include all
the information needed to use EPKINLY safely and effectively. See full
prescribing information for EPKINLY. EPKINLYTM (epcoritamab-bysp)
injection, for subcutaneous use Initial U.S. Approval: 2023 [Internet].
dailymed.nlm.nih.gov. [cited 2024 Feb 16]. Available from: https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a
23. These highlights do not include all
the information needed to use EPKINLY safely and effectively. See full
prescribing information for EPKINLY. EPKINLYTM (epcoritamab-bysp)
injection, for subcutaneous use Initial U.S. Approval: 2023 [Internet].
dailymed.nlm.nih.gov. [cited 2024 Feb 16]. Available from: https://dailymed.nlm.nih.gov/dailymed/medguide.cfm?setid=d7836711-b677-412d-bf2d-0f7c8444103a#:~:text=Low%20blood%20cell%20counts%20are
24. Genentech: Press Releases | Sunday,
Dec 10, 2023 [Internet]. www.gene.com. [cited 2024 Feb 16]. Available from: https://www.gene.com/media/press-releases/15015/2023-12-10/new-data-for-genentechs-columvi-and-luns
25. What is 3L+ Follicular Lymphoma |
LUNSUMIOTM (mosunetuzumab-axgb) [Internet]. lunsumio. [cited 2024 Feb 16].
Available from: https://www.lunsumio.com/about/what-is-follicular-lymphoma.html
26. EPKINLYTM (epcoritamab-bysp)
Approved by U.S. Food and Drug Administration as the First and Only Bispecific
Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell
Lymphoma (DLBCL) - Genmab A/S [Internet]. Genmab A/S. 2023 [cited 2024 Feb 16].
Available from: https://ir.genmab.com/news-releases/news-release-details/epkinlytm-epcoritamab-bysp-approved-us-food-and-drug